Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Ankeda (bevacizumab biosimilar) in non-squamous NSCLC in China
ChiCTR2000039826Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1101 in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Objective response rate. Started Aug 2020; status: recruiting.
02
Drugs
QL1101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000039826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039826.